Contact
Header_1077x260px_About_Profil.jpg

Profil explores opportunities for artificial pancreas in type 2 diabetes

Highlighting the role of open and trans-sectoral collaboration in the advancement of artificial pancreas solutions

Profil has recently published a peer-reviewed article on the topic of “Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project ” in the Journal of Diabetes Science and Technology. Profil is the organisation coordinating CLOSE. The article is authored by CLOSE industry and academic partners, representatives of the EIT Health public-private partnership management boards, and key opinion leaders in the field.

ehealthFigure 1: ehealth [Designed by Creativeart / Freepik]

The paper makes a  contribution to the recent discussion on the possible roles of artificial pancreas systems in type 2 diabetes care.  The paper explains the CLOSE approach to matching the diversity of people with type 2 diabetes and their care environments. The trans-sectoral architecture of the CLOSE partnership, the curation of the project as part of the EIT Health innovation portfolio, and the integrated advancement of technology, education, and business creation are considered key factors for the success of CLOSE. Beyond its unique capabilities in the clinical evaluation of diabetes technologies Profil contributes years of experience with coordinating the large European AP@home consortium and developing a CE-marked medical product that uses a glucose clamp technology (ClampArt®) in a closed-loop setting.

The complete article “Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project” can be downloaded here.

CLOSE (Automated Glucose Control at Home for People with Chronic Disease) [1] stands for a project designed to overcome artificial pancreas (AP) implementation barriers. The primary objective of the project is to develop superior risk-benefit and cost-benefit scenarios for AP operation thereby achieving a positive acceptance by users and caregivers and a high eligibility for reimbursement. In order to meet this objective the project will put the AP into the center of comprehensive product and service packages (APplus) specifically tailored to defined T2D patient groups and care environments. In the design of APplus solutions the project is going to realize an interactive collaboration with users, healthcare providers and other stakeholders in diabetes care. In a first step CLOSE will establish a scalable APplus model case working at the interface between patients, homecare service providers, and payers in France. CLOSE will then scale up APplus by pursuing geographic distribution, targeting additional audiences and by enhancing AP functionalities and interconnectedness.

 

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Oct 2, 2018 5:18:00 PM
Prof.

Subscribe to our monthly blog updates

Neuer Call-to-Action  

Subscribe to Email Updates

Our most popular Posts